Floatz Rating
B63/100
Confidence
Indicative
Sponsor
Beijing Pearl Biotechnology Limited Liability Company
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
62High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07285148CT.gov A Study to Evaluate ANS014004 in Combination With EGFR-TKI in Non-Small Cell Lung Cancer | — | Not Yet Recruiting | — | — | — |
NCT07295821CT.gov Osimertinib Induction and Maintenance for Chemo-ineligible Stage III Unresectable EGFR+ NSCLC: Single-arm Study | — | Recruiting | — | — | — |
NCT06618287CT.gov A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT06014827CT.gov Biologically Guided Radiation Therapy (BgRT) and Stereotactic Body Radiation Therapy (SBRT) to Tyrosine Kinase Inhibitor in Oligoprogressive Oncogenic Positive Non-Small Cell Lung Carcinoma | — | Recruiting | — | — | — |
NCT06538038CT.gov Prospective Non-Interventional Study Comparing Osimertinib +/- Chemotherapy for EGFR-Mutated NSCLC Patients | — | Recruiting | — | — | — |
NCT06194448CT.gov To Evaluate the Efficacy/Safety of Osimertinib Prior to CRT and Maintenance of it With Stage III, Unresectable NSCLC With EGFR Mutations | — | Active Not Recruiting | — | — | — |
NCT06323148CT.gov Adjuvant Target Therapy Guided by ctDNA-MRD in Patients With EGFR-mutant II-IIIA Non-small Cell Lung Cancer (ECTOP-1022) | — | Not Yet Recruiting | — | — | — |
NCT06067776CT.gov Osimertinib, Cetuximab, and Tucatinib for the Treatment of EGFR-Mutant Stage IV or Recurrent Non-small Lung Cell Cancer | — | Not Yet Recruiting | — | — | — |
NCT05401110CT.gov Study of Osimertinib With Carotuximab in Advanced, EGFR-mutated Non-Small Cell Lung Cancer | — | Recruiting | — | — | — |
NCT05624996CT.gov Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer | — | Recruiting | — | — | — |
Show 21 more trialsShow fewer
NCT05498389CT.gov EMB-01 in Combination With Osimertinib in Patients With EGFR Mutant Lung Cancer | — | Unknown | — | — | — |
NCT05642572CT.gov Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial) | — | Recruiting | — | — | — |
NCT05166616CT.gov Minnelide and Osimertinib for the Treatment of Advanced EGFR Mutated Non-Small Cell Lung Cancer | — | Active Not Recruiting | — | — | — |
NCT05017025CT.gov Aurora Kinase Inhibitor LY3295668 in Combination With Osimertinib for the Treatment of Advanced or Metastatic EGFR-Mutant Non-squamous Non-small Cell Lung Cancer | — | Active Not Recruiting | — | — | — |
NCT05215951CT.gov Osimertinib Plus Chemotherapy in Uncommon EGFRm NSCLC | — | Terminated | — | — | — |
NCT04780568CT.gov Osimertinib and Tegavivint as First-Line Therapy for the Treatment of Metastatic EGFR-Mutant Non-small Cell Lung Cancer | — | Recruiting | — | — | — |
NCT04988607CT.gov Osimertinib Plus Bevacizumab in Untreated EGFR Exon21 L858R Mutated NSCLC | — | Unknown | — | — | — |
NCT04762199CT.gov MRX-2843 and Osimertinib for the Treatment of Advanced EGFR Mutant Non-small Cell Lung Cancer | — | Recruiting | — | — | — |
NCT04285671CT.gov Necitumumab and Trastuzumab in Combination With Osimertinib for the Treatment of Refractory Epidermal Growth Factor Receptor (EGFR)-Mutated Stage IV Non-small Cell Lung Cancer | — | Active Not Recruiting | — | — | — |
NCT04181060CT.gov Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer | — | Recruiting | — | — | — |
NCT04545710CT.gov Osimertinib and Abemaciclib in EGFR Mutant Non-Small Cell Lung Cancer After Osimertinib Resistance | — | Active Not Recruiting | — | — | — |
NCT04479306CT.gov Osimertinib in Combination With Alisertib or Sapanisertib for the Treatment of Osimertinib-Resistant EGFR Mutant Stage IIIB or IV Non-Small Cell Lung Cancer | — | Completed | — | — | — |
NCT03831932CT.gov Telaglenastat Hydrochloride and Osimertinib in Treating Patients With EGFR-Mutated Stage IV Non-small Cell Lung Cancer | — | Active Not Recruiting | — | — | — |
NCT03804580CT.gov First-line Treatment With Osimertinib in EGFR-mutated Non-small Cell Lung Cancer | — | Unknown | — | — | — |
NCT02971501CT.gov Osimertinib With or Without Bevacizumab in Treating Patients With EGFR Positive Non-small Cell Lung Cancer and Brain Metastases | — | Active Not Recruiting | — | — | — |
NCT03455829CT.gov G1T38, a CDK 4/6 Inhibitor, in Combination With Osimertinib in EGFR-Mutant Non-Small Cell Lung Cancer | — | Completed | — | — | — |
NCT03410043CT.gov Osimertinib, Surgery, and Radiation Therapy in Treating Patients With Stage IIIB or IV Non-small Cell Lung Cancer With EGFR Mutations, NORTHSTAR Study | — | Active Not Recruiting | — | — | — |
NCT02917993CT.gov An Open-Label Phase 1/2 Study of Itacitinib in Combination With Osimertinib in Subjects With Non-Small Cell Lung Cancer | — | Completed | — | — | — |
NCT02496663CT.gov Osimertinib and Necitumumab in Treating Patients With EGFR-Mutant Stage IV or Recurrent Non-small Cell Lung Cancer Who Have Progressed on a Previous EGFR Tyrosine Kinase Inhibitor | — | Active Not Recruiting | — | — | — |
NCT02736513CT.gov Intracranial Activity of AZD9291 (TAGRISSO) in Advanced EGFRm NSCLC Patients With Asymptomatic Brain Metastases | — | Unknown | — | — | — |
NCT02504346CT.gov AZD9291, an Irreversible EGFR-TKI, in Relapsed EGFR-mutated Non-small Cell Lung Cancer Patients Previously Treated With an EGFR-TKI, Coupled to Extensive Translational Studies | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Lung Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Osimertinib (this asset) | Beijing Pearl Biotechnology Limited Liability Company | P3 | B · 63 |
| Cis-Diamminedichloroplatinum Ii | University of Vermont | P4 | BB |
| Carboplatin | SystImmune Inc. | P4 | BB |
| Desflurane | Peter MacCallum Cancer Centre, Australia | P4 | BB |
| Etoposide | SystImmune Inc. | P3 | BB |
| Nivolumab | University of Chicago | P4 | BB |
| Propofol | Kaohsiung Medical University Chung-Ho Memorial Hospital | P4 | BB |
| Vinorelbine Ditartrate | Alliance for Clinical Trials in Oncology | P3 | BB |
| Vinblastine | Intensity Therapeutics, Inc. | P3 | BB |
+42 more in the Lung Cancer cohort
Other indications for Osimertinib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Non-Small Cell Lung Carcinoma | — | P4 | BB · 71 |
| Lung Adenocarcinoma | — | P2 | BB · 69 |
| Hepatocellular Carcinoma | — | P3 | BB · 65 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Osimertinib in Lung Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/osimertinib-lung-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →